Gilead Sciences (NASDAQ:GILD) EVP Wettan Keeley Cain Sells 3,399 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) EVP Wettan Keeley Cain sold 3,399 shares of the stock in a transaction on Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the transaction, the executive vice president directly owned 5,360 shares of the company’s stock, valued at approximately $879,629.60. This trade represents a 38.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $169.32 on Tuesday. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. The business has a fifty day simple moving average of $153.51 and a two-hundred day simple moving average of $141.14. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The company has a market capitalization of $210.01 billion, a P/E ratio of -53.58 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same period in the previous year, the company posted $2.47 earnings per share. The business’s revenue was up 6.8% on a year-over-year basis. On average, analysts expect that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 1.9%. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Bank of Nova Scotia bought a new position in shares of Gilead Sciences during the second quarter valued at about $100,056,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Gilead Sciences in the second quarter worth about $55,754,000. Groupe la Francaise grew its stake in shares of Gilead Sciences by 30.9% in the second quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock worth $6,270,000 after purchasing an additional 11,712 shares during the last quarter. Baird Financial Group Inc. grew its stake in shares of Gilead Sciences by 3.6% in the second quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after purchasing an additional 10,206 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at about $6,251,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Jefferies Financial Group set a $196.00 price target on shares of Gilead Sciences in a research report on Wednesday, November 4th. Finally, JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $170.15.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.